IDIOPATHIC PULMONARY FIBROSIS bbt877-ipf-004

ELIGIBILITY & REQUIREMENTS

  • Aged 40 or older
  • Confirmed diagnosis of Idiopathic Pulmonary Fibrosis (IPF)

WHAT'S INVOLVED

  • The trial will run for approximately 34 weeks
  • 6 clinic visits to the Institute for Respiratory Health at QEII Medical Centre, Nedlands
  • A full health check by our doctors and nurses
  • Reimbursement for travel expenses
  • Personalised health care with our doctors and nurses

STUDY OUTLINE

This international research study will test BBT-877, an orally administered autotaxin inhibitor which is under development as a possible treatment for IPF.

Autotaxin is a substance that generates a compound (lysophosphatidic acid) which leads to the rapid production of new cells, inflammation and fibrosis – making the lungs less elastic. This process plays an important role in progression of IPF.

BBT-877 helps to inhibit autotaxin activity and in turn the production of lysophosphatidic acid.

To find out if this trial is suitable for you, please register below, or contact our Clinical Trials Team on 0419 011 766 or email clinicaltrials@resphealth.uwa.edu.au.

PRINCIPAL INVESTIGATOR

Dr Vidya Navaratnam (Nedlands)

LOCATION

Level 2, 6 Verdun Street Nedlands (within the Harry Perkins Institute)

REGISTER YOUR INTEREST IN THIS CLINICAL TRIAL

Address
Scroll to Top